The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas

Malignant gliomas are devastating neoplasia with limited curative treatment options. Temozolomide (TMZ, Temcat(®), Temodal(®) or Temodar(®)) is a first-line treatment for malignant gliomas but the development of drug resistance remains a major concern. Activating transcription factor 4 (ATF4) is a c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Chen, Daishi, Rauh, Manfred, Buchfelder, Michael, Eyupoglu, Ilker Y., Savaskan, Nicolai
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2017
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5584239/
https://ncbi.nlm.nih.gov/pubmed/28881638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17737
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller